Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

This study is testing a new type of radiation therapy called AB001 — an alpha-particle radioligand therapy that delivers targeted radiation directly to prostate cancer cells via a protein they express (PSMA) — for men with advanced prostate cancer that no longer responds to hormone therapy. **You may be eligible if...** - You are a male, age 18 or older, with progressing castration-resistant prostate cancer - You have already received at least one hormonal therapy drug (like enzalutamide or abiraterone) - You have at least one PSMA-avid metastatic lesion on a PSMA scan - You have adequate blood, kidney, and liver function - If applicable: prior lutetium-177 PSMA therapy (for one study group) **You may NOT be eligible if...** - You have untreated or active brain metastases - You have signs of spinal cord compression - You have a history of myelodysplastic syndrome or treatment-related leukemia - You have a bladder or kidney blockage - You have another active cancer requiring treatment within the past 2 years Talk to your doctor to see if this trial is right for you.